Nickolas Thomas L, Jamal Sophie A
Department of Medicine, Nephrology, Columbia University Medical Center, 622 West 168th Street, PH4-124, New York, NY, 10032, USA.
Rev Endocr Metab Disord. 2015 Jun;16(2):157-63. doi: 10.1007/s11154-015-9314-3.
The fact that bone disease and kidney disease co-exist is well known. Formally, this inter-relationship is called chronic kidney disease mineral bone disorder or CKD-MBD. Traditionally, it was thought that bone played a passive role in CKD-MBD - specifically that kidney disease caused disordered mineral metabolism which resulted in bone disease and ultimately fractures. More recently however our understanding of bone function in general and the role that bone plays in CKD-MBD in particular, has changed. This chapter will briefly review epidemiology of fractures in chronic kidney disease (CKD) and the roles that imaging and measuring markers of mineral metabolism can play in assessing fracture risk. We will then review more recent data consistent with the concept MBD occurs early in the course of CKD and, via the secretion of novel molecules and/or signalling pathways, the bone can influence other organ systems.
骨病与肾病共存这一事实广为人知。正式来讲,这种相互关系被称为慢性肾脏病矿物质骨代谢紊乱(CKD-MBD)。传统上,人们认为在CKD-MBD中骨骼起被动作用,具体而言,肾病会导致矿物质代谢紊乱,进而引发骨病并最终导致骨折。然而,近年来,我们对骨骼的总体功能,尤其是骨骼在CKD-MBD中所起的作用的理解发生了变化。本章将简要回顾慢性肾脏病(CKD)患者骨折的流行病学情况,以及矿物质代谢成像和测量标志物在评估骨折风险中所起的作用。然后,我们将回顾更多最新数据,这些数据与MBD在CKD病程早期就已出现的概念相一致,并且通过新分子的分泌和/或信号通路,骨骼可以影响其他器官系统。